Antiviral Platform Animation
SCIENTIFIC ANIMATION | Investor relations activities
We produced this medical animation for Cidara Therapeutics to explore their Cloudbreak® antiviral platform which is a fundamentally new approach to treating and preventing viral infections.
This mechanism of action (MoA) animation explores this technology platform and its revolutionary approach in the fight against life-threatening infectious diseases. Antiviral Fc-Conjugates (AVCs) are a new class of drugs developed from Cidara’s Cloudbreak® antiviral platform.
AVCs have the potential to prevent as well as treat influenza and other life-threatening viral diseases such as those caused by RSV, HIV, and other viral infections. These long-acting AVCs directly prevent viral proliferation whilst simultaneously engaging the immune system, maximizing viral clearance.
This animation was created for use as part of Cidara’s Investor Relations activities in order to educate potential investors on the science of this platform. Imagery and short clips from the animation have been utilized throughout their corporate presentations.
The video has been embedded onto the Cidara Therapeutics website as well as the Cidara YouTube Channel. Imagery from the animation is also found throughout the website, including an annotated image of AVC binding.
Are you interested in seeing how our award-winning medical animation can help you?
Random42 constantly strives to innovate in the medical animation space. Get in touch for a consultation on your next project.
‘‘Extremely happy, everybody was great on the team. They answered all our questions and made it look easy. The end result is perfect. ’’
Executive Coordinator, Cellectar Biosciences
‘‘The presentation was dramatically enhanced by the video, which looked fantastic on the big screen. Thank you and the entire Random42 team for your excellent work and for getting the final edition to me in time for the conference. All very much appreciated! ’’
President and CEO, Vallum Corporation
‘‘The quality of the work produced by Random42 sets them apart and helps us quickly tell our scientific story more clearly. The high-quality production value is bolstered by their depth of knowledge. Together, that helps us tell the story of a complex disease and cell-based treatment and make it understandable to professionals and laypeople alike.’’
CEO, Brainstorm Cell Therapeutics
‘‘Working with the Random42 team was a seamless collaboration, where they exhibited great project management skills, clear & thoughtful communication, and delivered high-quality work that was visually appealing. Our team was impressed with the final products!’’
Medical Affairs, Phathom Pharmaceuticals